SEC Form 4 · accession 0000899866-15-000082
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard Bell
Officer — CEO · Director
Period of report
Mar 19, 2015
Accepted (ET)
Mar 20, 2015 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1,F2 | Mar 19, 2015 | S | 15,952 | $188.07 | D | 949,426 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- F2The sale of common stock reported by this Form 4 consists of shares of Alexion common stock contributed by the reporting person to an exchange fund in exchange for shares of the exchange fund. The Alexion shares were valued at $188.07 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person.